Related Experiment Videos
[Fundamental study of piperacillin sodium in term and premature neonates]
T Watanabe1, I Nakamura, T Nonoda
1Department of Pediatrics, Nagoya National Hospital.
Insights
Piperacillin sodium (PIPC) is a safe and effective antibiotic for treating infections in neonates. Pharmacokinetic studies showed predictable drug behavior and no observed adverse effects, supporting its use in this population.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Infectious Diseases
Context:
- Neonatal infections pose significant risks.
- Broad-spectrum antibiotics are crucial for treating bacterial infections in neonates.
- Piperacillin sodium (PIPC) is a semisynthetic penicillin with demonstrated antibacterial activity.
Purpose:
- To investigate the pharmacokinetic profile and safety of piperacillin sodium (PIPC) in neonates.
- To evaluate the relationship between PIPC's half-life (T1/2) and postnatal age.
- To assess the clinical utility of PIPC for treating neonatal infections.
Summary:
- Pharmacokinetic parameters (half-life, distribution volume, total body clearance) of PIPC were examined in 10 neonates following a 50 mg/kg intravenous infusion.
- A clear correlation was established between PIPC's half-life and the hours after birth.
- No adverse effects or significant laboratory abnormalities were detected during the study.
Impact:
- Piperacillin sodium (PIPC) demonstrates favorable pharmacokinetics and a good safety profile in neonates.
- The findings suggest PIPC is a potentially valuable therapeutic option for bacterial infections in both mature and premature neonates.
- Further clinical studies may confirm PIPC's efficacy in treating a range of neonatal infections.
Abstract:
Piperacillin sodium (PIPC) is a semisynthetic penicillin displaying high antibacterial activities against Gram-positive and Gram-negative bacteria including Pseudomonas sp., Proteus sp., etc. It acts bactericidally and is stable against beta-lactamases. The usefulness of PIPC in the treatment of infections in mature and premature neonates was investigated and the following results were obtained. The pharmacokinetics (half-life, distribution volume, total body clearance) of PIPC after 50 mg/kg intravenous drip infusion in 10 cases of neonates were examined. Relationship between T1/2 and hours after birth was clearly determined. Adverse effects and abnormality in laboratory test values were not observed. It is considered from the above results that PIPC may be an useful antibacterial agent for the treatment of infections in neonates.